PRTA logo

PRTA
Prothena Corporation plc

1,988
Mkt Cap
$530.79M
Volume
200,125.00
52W High
$11.69
52W Low
$4.32
PE Ratio
-2.17
PRTA Fundamentals
Price
$9.99
Prev Close
$9.86
Open
$9.93
50D MA
$9.19
Beta
1.06
Avg. Volume
601,258.18
EPS (Annual)
-$4.53
P/B
1.89
Rev/Employee
$144,537.31
$214.91
Loading...
Loading...
News
all
press releases
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Zacks·6d ago
News Placeholder
JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA
JPMorgan Chase & Co. lifted its stake in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 479.6% during the third quarter, according to the company in its most recent Form 13F filing...
MarketBeat·6d ago
News Placeholder
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
Zacks·7d ago
News Placeholder
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·10d ago
News Placeholder
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has been assigned a consensus rating of "Hold" from the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Two...
MarketBeat·10d ago
News Placeholder
Why Is Jazz (JAZZ) Down 3.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·11d ago
News Placeholder
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·11d ago
News Placeholder
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
Prothena (NASDAQ:PRTA) Share Price Crosses Below 200-Day Moving Average - Time to Sell...
MarketBeat·13d ago
News Placeholder
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinsons and Alzheimers Disease at AD/PD 2026
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire·16d ago
<
1
2
...
>

Latest PRTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.